Recent News

• 03.23.2026 - Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
• 03.18.2026 - Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren’s Syndrome
• 03.12.2026 - Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
• 03.11.2026 - Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
• 03.10.2026 - Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
• 03.10.2026 - Trinity Biotech Provides Business and Trading Update
• 02.25.2026 - Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives

Recent Filings

• 03.16.2026 - EX-99.1 EX-99.1
• 03.16.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.10.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.10.2026 - EX-99.1 EX-99.1
• 03.10.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.10.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.10.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.06.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.04.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.03.2026 - EFFECT Notice of Effectiveness